



8. A combination therapeutic product according to claim 1, wherein the β -lactam antibiotic is selected from one or more of aztreonam, temocillin, piperacillin, cefpodoxime, ceftazidime, cefotaxime, ceftriaxone, meropenem, faropenem, imipenem, loracarbef, ceftobiprole or ceftaroline.

9. A combination therapeutic product according to claim 8, wherein the one or more β -lactam antibiotic is selected from aztreonam, ceftazidime or meropenem.

10. (canceled)

11. A pharmaceutical composition comprising a combination therapeutic product according to claim 1, or a compound of Formula I according to claim 1, in association with a pharmaceutically-acceptable excipient or carrier.

12-13. (canceled)

14. A method for the treatment of a *Strenotrophomonas maltophilia*, tuberculosis or *Pseudomonas* infection comprising simultaneously, sequentially or separately administering an effective amount of a combination therapeutic product according to claim 1, or a pharmaceutical compo-

sition comprising a combination therapeutic product according to claim 1, or a compound of Formula I according to claim 1, in association with a pharmaceutically-acceptable excipient or carrier.

15. A method of treating a *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infection, the method comprising administering to a patient in need of such treatment a β -lactamase inhibitor of Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in combination with one or more β -lactam antibiotics.

16. A method of potentiating the effect of a β -lactam antibiotic for the treatment of a *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infection, the method comprising the administration of a β -lactamase inhibitor of Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in combination with the β -lactam antibiotic.

17. A kit of parts comprising the following components:

- (i) a β -lactamase inhibitor of Formula I, as defined in claim 1, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier; and
- (ii) a β -lactam antibiotic, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier,

wherein the components are provided in a form which is suitable for sequential, separate and/or simultaneous administration.

18. A kit according to claim 17, for use in the treatment of a *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infection.

* * * * *